Rhythm Pharmaceuticals Inc.
RYTM
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
122.4% downsideOvervalued by 122.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.00 Billion |
|---|---|
| Enterprise Value | $7.17 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.11 |
| Beta | 1.88 |
| Outstanding Shares | 67,974,193 |
Return
| Return on Equity | -169.28% |
|---|---|
| Return on Assets | -47.04% |
| Return on Invested Capital | -54.28% |
Valuation & Multiples
| P/E Ratio | -32.62 |
|---|---|
| PEG | -262.92 |
| Price to Sales | 35.51 |
| Price to Book Ratio | 106.53 |
| Enterprise Value to Revenue | 33.01 |
| Enterprise Value to EBIT | -38.94 |
| Enterprise Value to Net Income | -35 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 1.85 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 13.32% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.51%▼ 109.50% |
|---|---|
| Total Invested | $38.49M▼ 99.40% |
| Investors Holding | 39▼ 252.00% |
ESG Score
No data
About Rhythm Pharmaceuticals Inc.
90 employees
CEO: Hunter Smith Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the mel...
Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policy, which is critical for the commercial success of high-cost orphan drugs like setmelanotide.
This committee directly oversees the FDA and the drug approval process, which is the primary driver of Rhythm's stock value and operational viability.